# NGM Biopharmaceuticals, Inc clinical trials: 26 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 26 trials with NGM Biopharmaceuticals, Inc as lead sponsor, 1 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by NGM Biopharmaceuticals, Inc: 26 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/ngm-biopharmaceuticals-inc

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 26
- Recruiting or not yet: 1
- Read on: November 19, 2026

## Trials

The 25 newest of 26, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| April 6, 2026 | NCT07511972 | Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | NGM Biopharmaceuticals, Inc | Phase 2 | Withdrawn | CRC | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07511972) |
| June 24, 2025 | NCT07033026 | An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer... | NGM Biopharmaceuticals, Inc | Phase 2 | Recruiting | Colorectal Cancer, CRC (Colorectal Cancer), Cancer Cachexia | 136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07033026) |
| October 23, 2024 | NCT06654726 | A Multi-center Evaluation of Aldafermin in a Randomized, Double-blind, Placebo-controlled Study in Subjects With Primary Sclerosing... | NGM Biopharmaceuticals, Inc | Phase 2/3 | Withdrawn | Primary Sclerosing Cholangitis | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06654726) |
| April 5, 2022 | NCT05311618 | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | NGM Biopharmaceuticals, Inc | Phase 1 | Unknown | Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non Small Cell Lung Cancer, Cervical Cancer, Endocervical Cancer... | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05311618) |
| January 31, 2022 | NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | NGM Biopharmaceuticals, Inc | Phase 1 | Unknown | Pancreatic Cancer, Breast Cancer, Gastric Cancer, Non-small Cell Lung Cancer, Cervical Cancer, Endocervical Cancer... | 130 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05215574) |
| June 4, 2021 | NCT04913337 | Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | NGM Biopharmaceuticals, Inc | Phase 1/2 | Unknown | Mesothelioma, Glioblastoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Melanoma, Pancreatic Ductal... | 179 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04913337) |
| April 2, 2021 | NCT04828265 | Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese Subjects | NGM Biopharmaceuticals, Inc | Phase 1 | Completed | Healthy Male | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04828265) |
| April 1, 2021 | NCT04823702 | Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function | NGM Biopharmaceuticals, Inc | Phase 1 | Completed | Impaired Hepatic Function | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04823702) |
| October 9, 2020 | NCT04582318 | A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and... | NGM Biopharmaceuticals, Inc | Phase 1/2 | Terminated | SARS-CoV-2 Infection | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04582318) |
| July 10, 2020 | NCT04465955 | A Study of NGM621 in Participants With Geographic Atrophy | NGM Biopharmaceuticals, Inc | Phase 2 | Completed | Geographic Atrophy | 320 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04465955) |
| December 24, 2019 | NCT04210245 | Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4) | NGM Biopharmaceuticals, Inc | Phase 2 | Completed | Compensated Cirrhosis, Nonalcoholic Steatohepatitis | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04210245) |
| December 5, 2019 | NCT04187339 | Study of NGM395 in Adult Participants | NGM Biopharmaceuticals, Inc | Phase 1 | Completed | Obesity, NAFLD | 38 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04187339) |
| November 27, 2019 | NCT04179630 | Study of Aldafermin (NGM282) in Participants With Impaired Renal Function | NGM Biopharmaceuticals, Inc | Phase 1 | Completed | Impaired Renal Function | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04179630) |
| August 28, 2019 | NCT04068896 | Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy | NGM Biopharmaceuticals, Inc | Phase 1/2 | Completed | Pancreatic Cancer, Metastatic Castration-resistant Prostate Cancer, Bladder Cancer, Melanoma, Non-small Cell Lung... | 89 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04068896) |
| July 10, 2019 | NCT04014777 | Study of NGM621 in Participants With Geographic Atrophy | NGM Biopharmaceuticals, Inc | Phase 1 | Completed | Geographic Atrophy | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04014777) |
| April 11, 2019 | NCT03912532 | Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center... | NGM Biopharmaceuticals, Inc | Phase 2 | Completed | NASH - Nonalcoholic Steatohepatitis | 171 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03912532) |
| January 5, 2018 | NCT03392116 | Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects | NGM Biopharmaceuticals, Inc | Phase 1 | Completed | Cachexia | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03392116) |
| October 2, 2017 | NCT03298464 | Study of NGM313 in Obese Participants | NGM Biopharmaceuticals, Inc | Phase 1 | Completed | Obese | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03298464) |
| March 15, 2016 | NCT02708576 | Phase 1 Study of NGM313 in Healthy Adult Participants | NGM Biopharmaceuticals, Inc | Phase 1 | Completed | Obesity | 151 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02708576) |
| March 10, 2016 | NCT02704364 | A Study of NGM282 in Patients With Primary Sclerosing Cholangitis | NGM Biopharmaceuticals, Inc | Phase 2 | Completed | Primary Sclerosing Cholangitis | 62 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02704364) |
| January 7, 2016 | NCT02649062 | Study of NGM282 in Subjects With Functional Constipation and Healthy Individuals | NGM Biopharmaceuticals, Inc | Phase 1/2 | Completed | Functional Constipation | 31 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02649062) |
| May 13, 2015 | NCT02443116 | Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH) | NGM Biopharmaceuticals, Inc | Phase 2 | Completed | Nonalcoholic Steatohepatitis (NASH) | 254 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02443116) |
| May 12, 2014 | NCT02135536 | Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis | NGM Biopharmaceuticals, Inc | Phase 2 | Completed | Primary Biliary Cirrhosis | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02135536) |
| January 3, 2014 | NCT02026401 | Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis | NGM Biopharmaceuticals, Inc | Phase 2 | Completed | Primary Biliary Cirrhosis | 45 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02026401) |
| September 16, 2013 | NCT01943045 | Phase 2 Study of NGM282 in Patients With Type 2 Diabetes | NGM Biopharmaceuticals, Inc | Phase 2 | Completed | Diabetes Mellitus | 81 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01943045) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 11 |
| Phase 1/2 | 4 |
| Phase 2 | 10 |
| Phase 2/3 | 1 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 19 |
| Unknown | 3 |
| Withdrawn | 2 |
| Terminated | 1 |
| Recruiting | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Colorectal Neoplasms | 5 |
| Non-alcoholic Fatty Liver Disease | 4 |
| Melanoma | 4 |
| Carcinoma, Non-Small-Cell Lung | 4 |
| Stomach Neoplasms | 4 |
| Esophageal Neoplasms | 4 |
| Ovarian Neoplasms | 4 |
| Squamous Cell Carcinoma of Head and Neck | 4 |
| Pancreatic Neoplasms | 3 |
| Prostatic Neoplasms | 3 |
| Obesity | 3 |
| Breast Neoplasms | 3 |
| Uterine Cervical Neoplasms | 3 |
| Carcinoma, Renal Cell | 3 |
| Mesothelioma | 3 |
| Cholangiocarcinoma | 3 |
| Geographic Atrophy | 2 |
| Liver Cirrhosis, Biliary | 2 |
| Diabetes Mellitus | 2 |
| Cholangitis, Sclerosing | 2 |
| Urinary Bladder Neoplasms | 1 |
| Cachexia | 1 |
| COVID-19 | 1 |
| Glioblastoma | 1 |
| Renal Insufficiency | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Stock brokers in the United States](https://specstream.ai/data/businesses/stock-brokers/united-states)
- [Commercial refrigeration companies in the United States](https://specstream.ai/data/businesses/commercial-refrigeration-companies/united-states)
- [Medical billing companies in the United States](https://specstream.ai/data/businesses/medical-billing-companies/united-states)
- [Walk-in clinics in the United States](https://specstream.ai/data/businesses/walk-in-clinics/united-states)
- [Elevator companies in the United States](https://specstream.ai/data/businesses/elevator-companies/united-states)
- [Pediatric clinics in the United States](https://specstream.ai/data/businesses/pediatric-clinics/united-states)
